Vastustamme Valviran aikeita puuttua kilpirauhasongelmien hoitoon

Ville pöntysen blogin  https://villepontynen.blogspot.fi/   mukaan on valviran inkvisiittorien kokous 18.12.2017. Harmillisesti vasta tammikuussa on tulossa huipputason tiedelehteen Euroopan ykköstutkijoiden tiimiltä mielenkiintoinen yhteenveto monien vuosien tutkimuksista. Erittäin tervetullut, koska tiimillä ei ole omaa nettisivustoa kuten Biancolla.

Eräs tutkijoista kertoo kirjoituksesta näin:

”,,,shows a) in control and expression of thyroid activity everyone is an individual – so that mere placement of values in or out of range is not diagnostically helpful or appropriate. b) TSH is unsuitable for monitoring thyroid hormone therapy, especially T4-only. All parameters TSH, FT4 and FT3 must be used in diagnosis c) the response of a person to thyroid dysfunction is unique and needs therefore unique individual treatment and control of treatment modalities. d) all Randomized Clinical Trials attempting to assess i) preferences for combined T4-T3 treatment over T4-only, and ii) those trying to show correlations between suppressed TSH and atrial fibrillation and osteoporosis are as a class wrongly devised and cannot demonstrate satisfactorily the phenomena they are studying. This comes about from a statistical error that all the studies have made in using nonselection in choosing their patient panels.”

https://www.frontiersin.org/articles/10.3389/fendo.2017.00364/abstract on linkki yhteenvetoon